LY-3381916 is a selective androgen receptor degrader (SARD) currently under investigation for the treatment of prostate cancer. It functions by binding to androgen receptors and promoting their degradation, thereby inhibiting androgen receptor signaling, which is a key driver in the progression of prostate cancer. This mechanism is particularly relevant in castration-resistant prostate cancer (CRPC), where tumors continue to grow despite low levels of androgens. By reducing the levels of functional androgen receptors, LY-3381916 may help suppress tumor growth and delay disease progression. Its oral bioavailability and targeted action make it a promising candidate in the development of next-generation therapies for advanced prostate cancer. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing in patients.